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Retrospective analysisdisease progression in the BSC arm of the randomised study.
Patients and methods: This was a single-arm study of the BSC patients of the randomised
study in whom disease progressed. Trabectedin (1.2 mg/m2) was administered over 24 h on
day 1 of a 21-d treatment cycle. The efficacy and safety of trabectedin after BSC were evalu-
ated and retrospectively compared with the results of the randomised study.
Results: Thirty patients crossed over to trabectedin. Median progression-free survival (PFS)
was 7.3 months (95% confidence interval [CI]: 2.9e9.1) after crossover compared with 0.9
months (95% CI: 0.9e1.0) at BSC in the randomised study. PFS in the present study was com-
parable to that of the trabectedin arm in the randomised study. The number of patients with
growth modulation index 1.33 was 25 (86%). Individual tumour volume was decreased in 11
patients after crossover. Adverse drug reactions (ADRs) were observed in 27 patients (96.4%).
ADRs of grade IIIeIV were mainly bone marrow suppression and abnormal liver functions.
Conclusion: Trabectedin was revealed to be effective and well tolerated in the identical patients
crossed over to trabectedin after disease progression in BSC.
The present study is registered with the Japan Pharmaceutical Information Center, number
JapicCTI-121853.
ª 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Soft tissue sarcomas (STS) are remarkably rare solid
tumours, accounting for <1% of all adult malignancies,
and classified into more than 50 histological subtypes.
Molecular biology has recently played a strong role in
STS diagnosis. One-third of STS subtypes are classified
as translocation-related sarcomas (TRS) [1], which can
be particularly interesting as a therapeutic target
because TRS provide specific biological insights and
mechanisms of action that may have an impact on
prognosis or therapy [2]. Chemotherapy is used for the
treatment of advanced STS. Over the past decades,
doxorubicin, either alone or in combination with ifos-
famide, has been used as first-line chemotherapy in most
of STS subgroups; however, the response rates are as
low as 20e30% [3,4]. Furthermore, therapeutic options
after failure of doxorubicin and/or ifosfamide are
limited [5].
Trabectedin is a marine-derived tetrahydroisoquino-
line alkaloid [6]. Trabectedin is approved by the Euro-
pean Medicines Authority for the treatment of advanced
STS in adults after failure of anthracyclines and ifosfa-
mide or when unsuited to receive these agents based on
the results of a pivotal phase II study, which indicated
superior disease control by trabectedin given 1.5 mg/m2
as a single infusion lasting 24 h every 3 weeks (q3week,
24 h) [7]. Trabectedin binds to the DNA minor groove,
and has indirect anti-inflammatory and anti-angiogenic
activity via tumour-associated macrophages [8]. It is
noted that trabectedin also modulates the transcription
of oncogenic fusion protein of TRS. Interestingly, the
cytotoxic sensitivity of trabectedin correlates to the
expression of different variants of the fusion protein
[9,10].We conducted a multicentre, open-label, randomised
phase II study comparing trabectedin with the best
supportive care (BSC) in patients with advanced TRS
after failure of standard chemotherapy [11]. As previ-
ously reported, this randomised study showed the clin-
ical benefit of trabectedin when administered at 1.2 mg/
m2 q3week, 24 h. The trabectedin dose of 1.2 mg/m2 was
based on the result of a phase I study in STS patients in
Japan [12]. Seventy-six patients were randomised to
receive either trabectedin or BSC in the randomised
study, and 73 patients (37 in the trabectedin arm and 36
in the BSC arm) were included in the efficacy analysis
[11].
The aim of the present study was to evaluate the ef-
ficacy and safety of trabectedin in patients crossed over
to trabectedin after disease progression while undergo-
ing BSC. We report a retrospective comparison of these
two studies.
2. Patients and methods
2.1. Patients
Patients who were assigned to BSC in the randomised
study and whose disease progressed afterwards accord-
ing to Response Evaluation Criteria in Solid Tumours
(RECIST) version 1.1 were allowed to crossover to
trabectedin (Fig. 1). During BSC, patients did not
receive anti-tumour therapy but did receive treatment to
relieve symptoms induced by primary disease and
improve quality of life. Most eligibility criteria of the
present study were the same as in the randomised study
[11]. In brief, eligible patients were pathologically diag-
nosed as a subtype of TRS: myxoid/round cell lip-
osarcoma (MRCL), synovial sarcoma (SS), alveolar
76 enrolled
37 analysed for efficacy 
2 excluded (diagnosis as non-TRS by 
central assay) 
36 analysed for safety at cut off
3 excluded (still in their first cycle)
39 received trabectedin 37 received best supportive care
31 enrolled
21 discontinued
17 progressed
2 refused
2 adverse event
9 ongoing
30 received trabectedin
1 not received trabectedin 
(dead by primary disease)
29 analysed for efficacy
1 excluded (diagnosis as non-TRS by 
central assay)
28 analysed for safety at cut off
2 excluded (still in their first cycle)
Crossover 
to trabectedin
Randomised study
36 discontinue with disease 
progression
5 not enrolled (not eligible) 
1 ongoing
Fig. 1. Patient disposition. TRS: translocation-related sarcomas.
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primitive neuroectodermal tumour, dermatofi-
brosarcoma protuberans, low grade fibromyxoid sar-
coma, alveolar soft part sarcoma, clear cell sarcoma,
angiomatoid fibrous histiocytoma, desmoplastic small
round cell tumour, extraskeletal myxoid chon-
drosarcoma, mesenchymal chondrosarcoma, giant cell
fibroblastoma, or endometrial stromal sarcoma.
The study protocol and the informed consent docu-
ments were approved by the institutional review board
at each study site. All patients gave written informed
consent before the initiation of any study-specific pro-
cedures. The study was conducted in accordance with
the ethical principles originating in or derived from the
Declaration of Helsinki, International Conference on
Harmonisation Good Clinical Practice Guidelines, and
locally applicable laws and regulations. Trabectedin was
supplied by Taiho Pharmaceutical Co., Ltd. (Tokyo,
Japan).
2.2. Treatment and assessments
Trabectedin (standard starting dose; 1.2 mg/m2) was
given via a central venous line over 24 h from
30 min after administration of dexamethasone and a 5-
HT3 receptor antagonist as antiemetic pretreatment on
day 1 of a 21-d cycle. The study treatment was repeateduntil disease progression, unmanageable toxicity, pa-
tient refusal, or delay for >21 d (one cycle) occurred
due to toxicity. Tumour assessment by computed to-
mography or magnetic resonance imaging was repeated
weeks 6, 12, 18, 24, and every 8 weeks thereafter in the
present study, while that of the randomised study was
repeated weeks 4, 8, 12, 18, 24, and every 8 weeks
thereafter.
Efficacy end-points were objective response rate
[ORR: the proportion of patients who achieved com-
plete response (CR) or partial response (PR)], disease
control rate (DCR: the proportion of patients with
CR, PR, or stable disease), progression-free survival
(PFS: the time from the day of enrollment in each
study until radiologic progression assessed by central
radiology imaging review or death by any cause),
progression-free rate (PFR) at 3 and 6 months
(KaplaneMeier estimate at each interval), and overall
survival (OS: the time from the day of enrollment in
each study until death by any cause). Time to pro-
gression (TTP) was defined as the time from the day of
enrollment in each study until radiologic progression
assessed by central radiology imaging review. Objec-
tive response was assessed according to RECIST
version 1.1. Adverse events (AEs) were graded ac-
cording to Common Terminology Criteria of Adverse
Events version 4.03.
Table 1
Demographics and baseline characteristics of patients.
Trabectedin
arm in
randomised
study (N Z 37)a
BSC arm in
randomised
study (N Z 29)
Crossed over
to trabectedin
(N Z 29)
n (%) n (%) n (%)
Gender
Male 21 (57) 17 (59)
Female 16 (43) 12 (41)
Age (years)
Median [range] 39.0 [21e77] 38.0 [25e60]
Eastern Cooperative Oncology Group
performance status
0 22 (60) 20 (69) 16 (55)
1 15 (41) 9 (31) 13 (45)
Histological typeb
Myxoid liposarcoma/round cell liposarcoma 14 (38) 8 (28)
Synovial sarcoma 7 (19) 10 (35)
Mesenchymal chondrosarcoma 3 (8) 3 (10)
Extraskeletal Ewing sarcoma/primitive
neuroectodermal tumour
3 (8) 2 (7)
Alveolar soft part sarcoma 3 (8) 1 (3)
Alveolar rhabdomyosarcoma 2 (5) 3 (10)
Extraskeletal myxoid chondrosarcoma 2 (5) 0 (0)
Dermatofibrosarcoma protuberans 1 (3) 0 (0)
Angiomatoid fibrous histiocytoma 1 (3) 0 (0)
Clear cell sarcoma 1 (3) 1 (3)
Desmoplastic small round cell tumour 0 (0) 1 (3)
Histological gradec
Low 2 (5) 0 (0)
Median 8 (22) 8 (28)
High 23 (62) 18 (62)
Not assessed or unknown 4 (11) 3 (10)
Translocation
Positive 31 (84) 25 (86)
Primary lesion
Lower limbs 21 (57) 15 (52)
Abdomen/pelvises 3 (8) 4 (14)
Intrathoracic 3 (8) 0 (0)
Neck 2 (5) 1 (3)
Face 1 (3) 4 (14)
Retroperitoneum 1 (3) 2 (7)
Other 6 (16) 3 (10)
Site by central radiology imaging reviewd
Lung 25 (68) 17 (59) 18 (62)
Peritonea 12 (32) 9 (31) 10 (35)
Lymph node 11 (30) 7 (24) 9 (31)
Pleura 11 (30) 7 (24) 8 (28)
Bone 11 (30) 4 (14) 5 (17)
Muscle 9 (24) 6 (21) 7 (24)
Other 10 (27) 4 (14) 5 (17)
Sum of the diameters of target lesions (mm)
Median [range] 91.70 [10.0e443.9] 93.30 [16.5e305.0] 134.20 [25.7e422.7]
Time from initial diagnosis to enrolled date
(months)
Median [range] 31.50 [3.4e225.0] 35.00 [2.5e166.7] 36.60 [2.7e167.3]
Number of regimen of prior systemic
anticancer agents
Median [range] 1.0 [0e3] 2.0 [0e4]
Post-treatmente
Yes 18 (49) 29 (100) 16 (55)
BSC, best supportive care.
Analysis set: Full analysis set (FAS).
a Data reported by Kawai et al. [11].
b Diagnosed at central pathological assay.
c Assessed according to French Fe´de´ration Nationale des Centres de Lutte Contre Le Cancer system system.
d Multiple answers were allowed.
e All patients in BSC arm in the randomised study were crossed over to trabectedin because six patients who were not crossed over were
excluded.
N. Araki et al. / European Journal of Cancer 56 (2016) 122e1301262.3. Statistical analysis
The efficacy was analysed in the full analysis set, which
was defined as patients who were histologically diag-
nosed as TRS by central pathological assay, received
trabectedin at least once, and had any tumour assess-
ment or survival follow-up. The KaplaneMeier method
was used to estimate PFS and OS, including 95% con-
fidence interval (CI). The inter-patient variability of PFS
and OS in the trabectedin arm of the randomised study
and crossover study were retrospectively evaluated. The
growth modulation index (GMI), which is used as a
measure of the activity of second-line treatment, is
calculated as follows; GMI Z TTPpresent study/TTPBSC
[13,14]. GMI 1.33 has been suggested as a criteria of
active drug. Intra-patient variability of change from
baseline in tumour volume was retrospectively
compared between the BSC arm of the randomised
study and that of trabectedin in the crossover study, and
was illustrated by individual patients. The safety was
analysed in the all-treated population, defined as the
patients who received trabectedin at least once.
The data cut-off date of both studies was February 8,
2014.Survival time (months)
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Fig. 2. (a) Comparison of KaplaneMeier curve of inter- and intra-pat
(c) individual intra-patient change from baseline in tumor volume. þC
lesion in the randomised study; zpatients with non-evaluable target lesi
myxoid liposarcoma and synovial sarcoma. TRS, translocation-related3. Results
Of the 36 patients whose disease progressed following
initial assignment to BSC in the randomised study, five
patients in the BSC arm were not enrolled in this study;
two patients received radiotherapy as a post-treatment,
two did not have any post-treatment, and one died
because of disease progression 1 d after termination of
the randomised study. Remaining 31 patients were
enrolled in the present study between August 20, 2012
and January 30, 2014. Of the 31 patients enrolled, 30
patients crossed over to trabectedin because one patient
died before receiving trabectedin (Fig. 1), and a total of
six patients (16%) of the BSC arm were not able to
crossover to trabectedin. Of the 30 patients crossed over
to trabectedin, the efficacy of trabectedin in 29 patients
was retrospectively compared in the trabectedin and
BSC arms, after excluding one patient who was diag-
nosed as non-TRS by central assay.
The patient characteristics are listed in Table 1.
Major subtypes of TRS were SS and MRCL. The me-
dian sum of diameters of target lesions by central radi-
ology image review in the present study was 134.2 mm
(range, 25.7e422.7). The median total number ofb
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Table 2
Tumour response by RECIST ver.1.1; overall and per histological
subtype.
Trabectedin arm of
randomised study
Crossover to
trabectedin
n (%) n (%)
All subtypes (N Z 37)a (N Z 29)
CR 0 (0) 0 (0)
PR 3 (8) 4 (14)
SD 21 (57) 16 (55)
PD 7 (19) 4 (14)
NE 6 (16) 5 (17)
Response rate (CRþPR) 3 (8) 4 (14)
95% CI (%) [1.7e21.9] [3.9e31.7]
Disease control rate
(CRþPRþSD)
24 (65) 20 (69)
95% CI (%) [47.5e79.8] [49.2e84.7]
Myxoid/round-cell liposarcoma (n Z 14) (n Z 8)
CR 0 (0) 0 (0)
PR 3 (21) 3 (38)
SD 8 (57) 5 (63)
PD 1 (7) 0 (0)
NE 2 (14) 0 (0)
Response rate (CRþPR) 3 (21) 3 (38)
95% CI (%) [4.7e50.8] [8.5e75.5]
Disease control rate
(CRþPRþSD)
11 (79) 8 (100)
95% CI (%) [49.2e95.3] [63.1e100.0]
Synovial sarcoma (n Z 7) (n Z 10)
CR 0 (0) 0 (0)
PR 0 (0) 1 (10)
SD 4 (57) 8 (80)
PD 2 (29) 0 (0)
NE 1 (14) 1 (10)
Response rate (CRþPR) 0 (0) 1 (10)
95% CI (%) [0.0e41.0] [0.3e44.5]
N. Araki et al. / European Journal of Cancer 56 (2016) 122e130 127trabectedin cycles was 4.0 (range, 1e14). The dose was
reduced in three patients (10.3%).
Median PFS was 7.3 months (95% CI: 2.9e9.1) in the
present study, while in the randomised study median
PFS for trabectedin and BSC was 5.6 months (95% CI:
4.1e7.5) and 0.9 months (95% CI: 0.9e1.0). Compari-
sons of KaplaneMeier curves of inter- and intra-patient
PFS are shown in Fig. 2a. Twenty five patients (86%)
had GMI 1.33 (Fig. 2b). Fig. 2c shows change from
baseline in tumour volume by individual patients. The
PFR at 3 and 6 months was 63.0% (95% CI: 43.5e82.4)
and 50.1% (95% CI: 27.7e72.4), while in the randomised
study PFR was 70.3% (95% CI: 53.9e86.8) and 44.0%
(95% CI: 24.4e63.6), respectively. ORR and DCR are
14% and 69% in all subtypes, 38% and 100% in MRCL
as listed in Table 2. TRS subtypes with PR to tra-
bectedin were MRCL in three patients and SS in one
patient. Radiological images of two of the PR cases after
crossover to trabectedin are shown in Fig. S1.
Median OS was 10.3 months (95% CI: 6.6enot
reached) in the present study (Fig. 3). The number of
deaths was 11 (37.9%), and cause of death in all cases
was disease progression. The number of censored cases
was 18 (62.1%), because these patients were alive at the
cut-off date.
Safety was assessed in 28 patients at data cutoff.
Sixteen serious adverse events were observed in nine
patients, and serious adverse drug reactions (SADRs)
were 12 in six patients. Among the 12 SADRs, four
events of bone-marrow suppression occurred in three
patients. These SADRs were recovered by adequate
treatment. AEs occurred in all patients, and 96.4% of
patients had drug-related AEs (Table 3). Highly
frequent AEs of grade III or IV were mainly bone
marrow suppression and abnormal liver functions. Two
patients withdrew from the study due to toxicity
(nausea, decreased appetite, vomiting, malaise, aspar-
tate aminotransferase increased, and alanine amino-
transferase increased). No drug-related deaths were
found during the study.
Disease control rate
(CRþPRþSD)
4 (57) 9 ( 90)
95% CI (%) [18.4e90.1] [55.5e99.7]
Other TRS (n Z 16) (n Z 11)
CR 0 (0) 0 (0)
PR 0 (0) 0 (0)
SD 9 (56) 3 (27)
PD 4 (25) 4 (36)
NE 3 (19) 4 (36)
Response rate (CRþPR) 0 (0) 0 (0)
95% CI (%) [0.0e20.6] [0.0e28.5]
Disease control rate
(CRþPRþSD)
9 (56) 3 (27)
95% CI (%) [29.9e80.2] [6.0e61.0]
Other TRS, subtypes other than myxoid liposarcoma and synovial
sarcoma; CR, complete response; PR, partial response; SD, stable
disease; PD, progressive disease; NE, not evaluable; RECIST,
Response Evaluation Criteria in Solid Tumours; TRS, translocation-
related sarcomas; CI, confidence interval.
a Data reported by Kawai et al. [11].4. Discussion
In the present study, we found that trabectedin was
effective and tolerable in patients with advanced TRS
after failure of standard chemotherapy even if patients
had passed through the duration of BSC.
We used only the data of patients in the BSC arm
who crossed over to trabectedin to compare the effi-
cacy in identical patients. Exclusion of six patients
who did not crossover to trabectedin from the retro-
spective analysis population would cause a potential
bias, predicting better outcome, because five of six
patients died within 5 months from the enrollment in
the randomised study, shorter than the overall median
OS.Patient characteristics in the present study were
similar to those in the randomised study, because the
present study was a continuation of the randomised
study, and patient characteristics were well balanced in
the randomised study. However, in intra-patient com-
parison, median size of the target lesion in the present
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Fig. 3. KaplaneMeier plot of overall survival. Overall survival of patients crossed over to trabectedin after randomised to BSC (e) and
those initially randomised to the trabectedin arm (---). BSC, best supportive care.
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of patients with performance status 1 was higher than
that in the BSC arm. In inter-patient comparison, me-
dian size of target lesion, time from initial diagnosis to
enrolled date, and number of regimens were slightly
different. These could have been affected by primary
disease progression during BSC. Numbers of dose
reduction or discontinuation, dose intensity, and relative
dose intensity were similar to those of the trabectedin
arm in the randomised study.
Median PFS in the BSC arm of the randomised study
was dramatically improved by crossing over to tra-
bectedin. Although patient characteristics in the present
study tended to be worse than those in the trabectedin
arm in the randomised study, PFS in the present study
was comparable to that of the trabectedin arm in the
randomised study.
Most of the patients progressed within 1 month in
BSC. Although disease is thought to progress as time
passes, 86% of patients had GMI 1.33, which means
33% improvement by trabectedin. Individual tumour
volume decreased in 11 patients after crossover. In the
patients whose tumour volume was not decreased after
crossover, progression was suppressed. These findings
indicate that the disease progression was controlled well
by trabectedin.
Le Cesne et al. [15] reported that median PFS in TRS
was 4.1 months (95% CI, 2.8e6.1) in a retrospective
analysis. The present study showed similar PFS in pa-
tients with TRS subtypes crossed over to 1.2 mg/m2
trabectedin.
This crossover study design with intra-patient retro-
spective analysis would be a useful method for con-
firming the efficacy and safety of a study drug in alimited number of clinical studies, as previously reported
by Zalcberg et al. [16] in a study of imatinib in gastro-
intestinal stromal tumour.
PFR of 63.0% at 3 months and 50.1% at 6 months
after crossover to trabectedin, as the median of third-
line treatment, notably exceeded the cutoff criteria for
second-line treatment of advanced STS, established by
the European Organisation for Research and Treatment
of Cancer (39% at 3 months and 14% at 6 months) [17].
ORR and DCR after crossover were nearly equal to
those in the trabectedin arm in the randomised study. It
is noteworthy that DCR was 100% in MRCL patients
after crossover. Median OS after crossover was 10.3
months at the cut-off date. The observation period was
short at about 18 months, and therefore the contribu-
tion of trabectedin to OS needs promising further
investigation.
As recently Le Cesne et al. [18] have reported that
continuation of trabectedin affects PFS prolongation in
STS patients, trabectedin has become a more important
role on the treatment for STS.
Major drug-related AEs with a high degree of
severity were myelosuppression and abnormal liver
functions. These were mostly reversible and manageable
by adequate treatment or arrangement of treatment in-
terval, with no cumulative toxicity with repeating cycles.
The safety profiles of trabectedin in the present study
were similar to those in the trabectedin arm in the
randomised study [11] and other studies of 1.5 mg/m2 of
trabectedin [19].
In conclusion, to our knowledge, this is the first intra-
patient comparison of trabectedin with BSC. Trabecte-
din was effective and tolerable even in patients crossed
over to trabectedin after disease progression within 1
Table 3
Trabectedin-related adverse events that occurred in 10% of patients.
Trabectedin
arm in
randomised
study (N Z 36)a
Crossed over
to trabectedin
(N Z 28)
G1 G3 G1 G3
n (%) n (%) n (%) n (%)
Any adverse events 36 (100) 34 (94) 28 (100) 26 (93)
Any adverse drug reactions 36 (100) 33 (92) 27 (96) 26 (93)
Adverse drug reactions (10% of patients)
Clinical findings
Nausea 32 (89) 3 (8) 25 (89) 1 (4)
Decreased appetite 21 (58) 2 (6) 20 (71) 3 (11)
Constipation 17 (47) 0 (0) 12 (43) 0 (0)
Malaise 16 (44) 0 (0) 18 (64) 0 (0)
Vomiting 14 (39) 0 (0) 9 (32) 0 (0)
Anaemia 11 (31) 7 (19) 7 (25) 7 (25)
Fatigue 6 (17) 1 (3) 5 (18) 0 (0)
Diarrhoea 6 (17) 1 (3) 3 (11) 0 (0)
Stomatitis 6 (17) 0 (0) 3 (11) 0 (0)
Pyrexia 6 (17) 0 (0) 3 (11) 0 (0)
Dysgeusia 5 (14) 0 (0) 3 (11) 0 (0)
Myalgia 5 (14) 0 (0) 3 (11) 0 (0)
Febrile neutropenia 5 (14) 5 (14) 5 (18) 5 (18)
Oedema peripheral 4 (11) 0 (0) 2 (7) 0 (0)
Hiccups 2 (6) 0 (0) 3 (11) 0 (0)
Non-haematological laboratory value
Alanine aminotransferase
increased
24 (67) 22 (61) 19 (68) 19 (68)
Aspartate aminotransferase
increased
17 (47) 15 (42) 18 (64) 15 (54)
Gamma-glutamyltransferase
increased
10 (28) 9 (25) 12 (43) 12 (43)
Blood bilirubin increased 4 (11) 0 (0) 2 (7) 0 (0)
Blood creatine
phosphokinase increased
4 (11) 1 (3) 1 (4) 0 (0)
Blood alkaline
phosphatase increased
3 (8) 2 (6) 6 (21) 0 (0)
Haematological laboratory value
Neutrophil count decreased 30 (83) 24 (67) 26 (93) 24 (86)
White blood cell count
decreased
20 (56) 20 (56) 19 (68) 19 (68)
Platelet count decreased 13 (36) 6 (17) 11 (39) 6 (21)
Lymphocyte count
decreased
8 (22) 8 (22) 6 (21) 6 (21)
BSC, best supportive care
Analysis set: all trabectedin-treated patients.
Total of five patients (two patients crossed over to trabectedin and
three patients in the randomised study in the BSC arm in the rando-
mised study) were excluded from this analysis because they were still in
their first treatment cycle at the analysis cutoff date.
Grade was evaluated according to the Common Terminology Criteria
for Adverse Events (CTCAE) version 4.03.
a Data reported by Kawai et al. [11].
N. Araki et al. / European Journal of Cancer 56 (2016) 122e130 129month in BSC. The results of the present study make the
effectiveness and safety of trabectedin confirmed in the
randomised study more robust. Our findings confirm the
role of trabectedin for patients with TRS after failure of
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